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ABSTRACT  
Background: Management of breast ductal carcinoma in situ (DCIS) has various 
approaches with distinct institutional specific practice. Here, we review DCIS management 
in a single institution with emphasise on re-operation rates and outcome. Methods: DCIS 
cases diagnosed at the Nottingham Breast Institute between 1987 and 2017 were identified 
(n=1,249). Clinicopathological data was collected. Cases were histologically reviewed, and 
different factors associated with primary operation selection, re-excision, presence of 
residual tumour in the re-excision specimens, use of radiotherapy and ipsilateral recurrences 
were analysed. Results: 34% of DCIS patients were initially treated by mastectomy and 
were more frequently symptomatic, of high nuclear tumour grade, size >40mm, and 
associated with comedo necrosis and Paget’s disease of the nipple. Further surgery was due 
to involved or narrow surgical margins. Residual tumour tissue was detected in 53% of the 
re-excision specimens. Re-excision rates of patients treated with breast conserving surgery 
(BCS) were reduced from approximately 70% to 23% and the final mastectomy rates 
decreased from 60% to 20%. Changes in surgical practice with acceptance of smaller 
excision margins and more frequent use of local radiotherapy have led to a significant 
decrease not only in the re-excision rate but also in the final mastectomy rate together with 
non-significant reduction in 5- and 10-year local recurrence rates. Conclusion: Although 
BCS is increasingly the preferred primary surgical option for DCIS management, a 
proportion of low-risk DCIS patients continue to undergo re-excision surgery or completion 
mastectomy. Despite acceptance of smaller margins, recurrence rate is decreasing.   
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INTRODUCTION  
Breast ductal carcinoma in situ (DCIS) represents about 10% of all breast carcinomas 1. Its 
incidence has increased dramatically in the UK since introduction of the mammographic 
screening programme, and currently it accounts for approximately 20-25% of 
mammographically screen detected breast carcinomas 2. The breakthrough of molecular 
techniques shows that DCIS is a heterogeneous group of diseases. Such heterogeneity is 
reflected in tumour behaviour and ideally the management approach needs to be designed 
accordingly to decrease the risk of progression and/or recurrence 3,4. Mastectomy was long 
considered the standard management for DCIS and remains so in certain situations (e.g. 
extensive disease, those with failed breast conservation, or where there are 
contraindications to radiotherapy (RT) in high-risk patients) 5,6. It provides an effective and 
near total cure rate; however, for most women it is an aggressive over-treatment of a lesion 
with low mortality risk with potential increased psychosocial morbidity and health economic 
costs 3. Breast-conserving surgery (BCS), with or without RT, is offered when DCIS can be 
removed with an acceptable cosmetic outcome and considered equivalent to mastectomy in 
terms of overall survival or breast cancer specific survival 1. However, studies report women 
treated with BCS have up to 15% risk of recurrence within 10 years and half of these 
recurrences are invasive disease with subsequent mortality risk 7,8. RT following BCS 
decreases the risk of recurrence to less than 10% at 10 years although clear guidelines for 
its indications in specific risk groups continue to be debated 9-13. Over- or under-treatment 
of DCIS remains a problem and numerous trials have been developed to assess more 
personalised therapy 14,15. Various factors affecting outcome of treated DCIS have been 
analysed and different risk groups can be stratified accordingly, aiding treatment decisions 
16. Age at diagnosis, clinical route of presentation, nuclear grade and lesion size, resection 
margin status are well recognised factors used for this purpose. The Van Nuys prognostic 
index (VNPI) is a popular risk assessment tool combining patient age, lesion size, nuclear 
grade and margin status (Supplementary table1) 17,18.  
Optimal extent of free resection margins after BCS is still controversial. A UK survey in 2007 
identified that approximately half of surgeons aim for a free margin of more than 2mm 19. 
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In 2016, the Society of Surgical Oncology, American Society for Radiation Oncology and 
American Society of Clinical Oncology consensus guideline on margins for BCS with whole-
breast irradiation in DCIS suggest a 2mm free surgical margin 20. Positive or close margins 
are the main indication for surgical re-excision or completion mastectomy after primary 
surgery for DCIS 21-23. In this retrospective study, we review the different management 
approaches across 30 years in a single institution and the different clinicopathological 
factors affecting them in a large cohort of women with DCIS diagnosed at the Nottingham 
Breast Institute between 1987-2017.  
PATIENTS AND METHODS 
All pure DCIS cases diagnosed between 1987-2017 at the Nottingham Breast Institute were 
identified (Table 1, n=1,249). Cases associated with invasive or micro-invasive carcinoma 
were excluded. Patients with multiple specimens; primary excision and re-excision 
specimen(s), were considered as a single surgical episode and size of any DCIS identified in 
the re-excision specimens was added to the size of tumour in the primary excision specimen 
to calculate the final size. Clinicopathological data including age at diagnosis, mode of DCIS 
presentation (screen-detected or symptomatic), size of the lesion, nuclear grade, presence 
of comedo necrosis, DCIS morphological type and associated Paget’s disease, was retrieved 
from patient records. Management options including primary operation type (BCS vs 
mastectomy), margins status, re-excision surgery and its type, presence of residual DCIS in 
the re-excised specimens and the final operation together with RT data were also collected. 
Resection margin status data was further categorised based on the recent 
recommendations; i.e. positive margin (tumour on ink), close margin (<2mm) and negative 
margin (≥2mm) 20,24. For comparison purposes; the whole cohort was further split into two 
groups; those diagnosed between 1987-2008 (n=803) and 2009-2017 (n=446). This was 
based on the guideline change with regard to margin of excision, soon after 2008, with 
acceptable free margin after BCS in DCIS of 5mm instead of 10mm free margin 3. Although, 
the service currently follows the new guidelines published in 2016 that recommend 2mm as 
optimal free margin in DCIS, cases managed in 2016 and 2017, in this study, were included 
in the latter group to avoid bias in statistical analysis. Five and ten-year local recurrence 
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free interval (LRFI) was estimated (in months). Five and ten-year local recurrence is defined 
as any event of ipsilateral tumour recurrence (either as DCIS or invasive disease) occurred 
after 6 months from the first DCIS surgery and up to 60 and 120 months; respectively.   
VNPI was assessed for all cases treated with BCS after the first operation (n=824) and the 
risk score was estimated. 
Statistical analysis  
Statistical analyses were performed using SPSS v21 (Chicago, IL, USA) for Windows.  Chi-
square test and the multivariate logistic regression model were used to correlate between 
different clinicopathological factors with primary operation preference, re-excision, type of 
re- excision, RT and presence of residual tumour tissue in the re-excised specimens. The 5 
and 10-year LRFI were compared between both periods by log rank test.  
This work obtained ethics approval by the North West – Greater Manchester Central 
Research Ethics Committee under the title; Nottingham Health Science Biobank (NHSB), 
reference number 15/NW/0685. 
RESULTS  
A total of 945/1,249 women (75%) diagnosed with DCIS were within the screening age 
group (50-70 years). High nuclear grade was observed in 61% of cases, while comedo type 
necrosis was recorded in two thirds of cases (67%). Solid DCIS was the predominant 
histological type, either in pure form or mixed with other morphological types and 
represented 58% of cases. Paget’s disease was observed in 56 (9%) cases.  
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Regarding DCIS management; 824 (66%) cases were treated primarily with BCS, while 
mastectomy was performed in 424 cases (34%). The latter was the first choice in those who 
presented symptomatically (p<0.0001), diffuse DCIS lesions involving more than one breast 
quadrant (p<0.0001), DCIS size more than 40mm (p<0.0001), high nuclear grade 
(p<0.0001), associated comedo necrosis (p<0.0001), and solid DCIS (p=0.030) (Table 2).  
After primary BCS, 317 (39%) cases showed positive margins (tumour on ink), while 88 
cases (11%) showed close margins less than 2mm. Free safety margin more than 10mm 
was observed in 20% of cases. Over the entire study period, half of the DCIS cases treated 
with BCS (n=414) underwent re-excision. The re-operation was either in the form of 
another conservative surgery (n=232) or completion mastectomy (n=182), (Table 3).  
Several factors influenced the rate of re-excision, including patients younger than 40 years 
old (p=0.028), symptomatic presentation (p<0.0001), lesions involving more than one 
breast quadrant (p=0.003), DCIS size more than 40mm (p<0.0001), presence of comedo 
necrosis (p=0.009), positive or close resection margins less than 2mm (p<0.0001) and high 
VNPI (p<0.0001). Moreover, presence of solid and/or micropapillary DCIS either in pure 
form or with other morphological types was associated with a higher rate of re-excision 
(p<0.0001). Figure 1a shows the rate of re-excision as regard to margin status. It is 
noteworthy that 196 (47%) of those who underwent re-excision were of low or intermediate 
grade. Moreover, 10% of low risk VNPI cases had a second operation. Supplementary figure 
1 shows the rate of re-excision in context of margin status, tumour grade and risk groups. 
Table 4 and supplementary table 2 show the detailed association between re-excision and 
type of re-excision with the clinicopathological variables.    
Completion mastectomy was more likely to be recommended for women younger than 40 
years old (p=0.018), with symptomatic DCIS (p<0.0001), multiple DCIS lesions or involving 
more than one breast quadrant (p=0.005), with DCIS more than 4cm in maximum diameter 
(p<0.0001), positive or close resection margin of less than 2mm (p<0.0001) and high-risk 
DCIS according to VNPI (p<0.0001).  
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Residual tumour tissue was detected in 218/414 cases (53%) who had re-excision surgery. 
Presence of residual tumour tissue in the re-excised specimens was associated with DCIS 
presenting symptomatically (p<0.0001), larger tumour size more than 40mm (p<0.0001), 
DCIS with cribriform morphology (p=0.018), positive or close margins less than 2mm 
(p=0.015) and high risk VNPI (p<0.0001). Patients who underwent completion mastectomy 
showed a higher rate of residual tumour tissue than those who had a second re-excision 
operation (p<0.0001). Supplementary table 3 shows the different factors associated with 
the presence of residual tumour tissue in the re-excision or completion mastectomy 
specimens.  
Multivariate logistic regression analysis showed that symptomatic DCIS, extent of the lesion, 
DCIS size, presence of comedo type necrosis and surgical margin status were the common 
independent factors affecting the rate of re-excision, type of re-excision and/or presence of 
residual tumour in the re-excised specimens. Table 5 summarise the multivariate logistic 
regression results.  
VNPI was assessed for all cases treated with BCS after the first operation (n=824) and risk 
score calculated (mean score was 7.7±1.7, range 4-12). Low, moderate and high risk DCIS 
was observed in 195 (25%), 470 (60%) and 118 (15%) cases respectively. VNPI could not 
be assessed in 41 (5%) cases because one or more of the index parameters was missing. 
263 out of 642 patients (41%) treated with BCS as a final surgery received post-operative 
adjuvant RT. Its use was associated with high risk DCIS features including tumour size more 
than 40mm (p<0.0001), higher tumour grade (p<0.0001), presence of comedo type 
necrosis (p<0.0001), positive or close surgical margins (p=0.008), and moderate and high 
risk DCIS (VNPI) (p<0.0001). Increased use of RT over the study period was observed.  
Over the period of the study, the management of DCIS showed significant changes with 
acceptance of smaller margins, improving quality of imaging detection of DCIS and more 
frequent use of local RT. Figure 1 shows details of the trends of primary and final BCS, RT 
rate, re-excision rate and local recurrence rate. As the most significant change in the margin 
status was introduced in 2008, this time point was used to compare the old and recent 
series of DCIS in this study. After 2008, a significant reduction in the rate of mastectomy as 
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a first operative choice for DCIS management was observed (p=0.015), along with a 
marked decrease in the rate of re-excision to 37% compared to 58% prior to 2008 
(p<0.0001) and an increase in the presence of residual DCIS in the re-excised specimens 
(p=0.04). Re-excision rate in 2017 was 23%.  
Importantly, the change in surgical practice after 2008, with acceptance of narrower surgical 
margins, was not hazardous in terms of the ipsilateral local recurrence rate. In contrast, the 
5-year recurrence rate decreased from 5.4% for DCIS managed between 1987-2008 to 
2.2% for DCIS managed after 2008. The same was observed in the 10-year recurrence rate 
which was 8.8% in the former and dropped to 2.5% in the latter. However, these differences 
did not show statistical significance (p value=0.223 and 0.225, respectively).  
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DISCUSSION  
Prior to the early 1990’s, the standard treatment for DCIS was mastectomy. However, BCS 
with adjuvant RT show comparable outcome to mastectomy in terms of recurrence free 
interval and overall survival and as a result, the rate of mastectomies has declined and BCS 
predominates 25,26. In the current study, documenting practice in a single institution over a 
30-year period, approximately two thirds of DCIS cases were treated with BCS as a first 
surgical modality. Mastectomy was the preferred option for patients with symptomatic DCIS, 
high tumour grade, larger sized tumours (>40mm), associated comedo necrosis and those 
involving more than one quadrant of the breast. Over the period of the study, there was not 
only an increase in the rates of initial BCS but also a significant decline in the re-excision 
and final mastectomy rates and more importantly in the ipsilateral local recurrences rate. 
Although a change in the local practice occurred in 2008, in which margin width of 5mm was 
accepted instead of 10mm, and a recent change of practice in 2016 in which 2mm margin 
was adopted, the frequency of BCS, re-excision rates and local recurrence rates showed 
gradual change over time rather than a sudden transition at this certain time point. This 
may reflect the impact of several factors including the improvement of imaging quality with 
better assessment of DCIS size and extent, quality of surgery, and the growing use of local 
RT.    
The current study demonstrates the radiological and pathological indications for BCS and 
the factors associated with the decision to perform additional therapeutic operations. The 
predominant factor in deciding BCS is the extent of the disease. Patient choice is also a 
contributing factor as evidenced by the NHS Breast Screening Programme where patient 
choice accounts for about 11% of mastectomies for DCIS 27. Recently, in the UK and US, the 
rate of mastectomy has increased particularly in young women perceived at high risk of 
further breast cancer events 6,28. In a report on 8,000 DCIS cases included in the Sloane 
Project and treated between 2003 and 2012 the rate of attempted BCS was 79% and 
successful BCS was 68% 27,29. Achieving success at BCS for DCIS remains a challenge and it 
continues to be the case that a woman with DCIS is at least as likely to have a mastectomy 
as a woman with invasive breast cancer (IBC). It is also reported that the re-excision rates 
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after BCS as a treatment for DCIS is higher than re-excisions for IBC. Furthermore, invasive 
disease accompanying DCIS has higher re-operation rates than pure invasive disease 30,31.  
The need to perform further surgery, re-excision or completion mastectomy, is governed 
predominantly by what is regarded as a minimum free resection margin. Positive margins is 
partly due to radiologic under-estimation of DCIS size which can occur in over 50% of cases 
29,32. Other studies, similar to the current findings, have shown that the diffuse DCIS growth 
patterns such as micropapillary and cribriform types, high nuclear grade DCIS with comedo 
type necrosis and high risk VNPI are factors associated with an increased rate of re-
excisions 31-34.   
The current study shows that half of the patients with DCIS who underwent re-excision, due 
to positive or close surgical margins, were of low and intermediate grade. This practice 
might have an impact on the pending outcome of recent trials for more conservative 
management of low risk DCIS 14,35. If safe, such strategies could significantly reduce re-
operation and mastectomy rates.    
In this study, half of the re-excised specimens were free of residual tumour, even though 
some cases were reported to have tumour on ink after the primary excision. Such a finding 
perhaps illustrates the controversy in pathological evaluation 24. Presence of residual DCIS 
was correlated to other adverse clinicopathological parameters i.e. symptomatic 
presentation, larger tumour size, DCIS with cribriform and micropapillary morphology. 
Previous studies were performed to establish a margin index based on tumour size and the 
closest surgical margin to show its association with presence of residual tumour tissue after 
re-excision, but this did not show significant association 36,37. Another study showed that the 
extent of margin involvement either focal or diffuse as well as the number of involved ducts 
in the closest margin were the main factors associated with presence of residual DCIS in the 
re-excision specimens 22. In our case series, an increased rate of residual tumour tissue in 
the re-excised specimens was found after 2008 perhaps reflecting a better overall strategy 
for further surgery.       
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Determining the optimal free margin for breast conservation remains a challenge 
particularly in pure DCIS. The Society of Surgical Oncology-American Society for Radiation 
Oncology has published new guidelines for the optimal margin in invasive disease and 
recommends no tumour on ink as a negative margin as there is no evidence that wider clear 
margins reduce ipsilateral recurrence 38. In DCIS, the same group published consensus 
guidelines suggesting 2mm as a standard for adequate surgical margin. Systematic review 
and meta-analysis of 20 studies showed that negative margins minimise the risk of 
ipsilateral recurrence by 50% compared with positive margins defined as tumour on ink. A 
2mm margin minimises the risk of recurrence compared with smaller negative margins 39-41. 
However, the agreement on these recommendations is different between centres and the 
choice of optimal margins depends mainly on the surgeons’ practice and methods of margin 
assessment by pathologists which was supported by the current National Institute for Health 
and Care Excellence (NICE) guidelines 42. Accepting closer margins of excision is a means of 
reducing re-operation rates, as has been shown in invasive disease 43. However, planning a 
wider macroscopic margin in higher risk cases or tailoring the scrutiny of margin 
assessment to the risk factors are other strategies. 
The acceptable optimal margin ranged from 1mm to > 10mm. In the current study, we 
grouped cases according to margin status using different classification schemes. Close 
surgical margins less than 2mm were significantly associated with an increased rate of re-
excision and presence of residual tumour tissue in the re-excised specimens which is 
consistent with other studies 22,44,45. Interestingly, change in surgical practice with 
acceptance of narrower free margin in patients treated conservatively did not increase the 
recurrence rate. This indicates better risk stratification, adjuvant radiotherapy (RT) selection 
and individualised management for patients based on constellation of all clinicopathological 
factors.   
All large prospective trials to evaluate the impact of adjuvant RT after DCIS BCS showed a 
50% reduction in recurrence rate with adjuvant RT 10,46,47. No specific group of patients 
were identified where RT could be safely avoided, hence the continued debate over RT 
indications after BCS. In routine practice, only about 30-50% of BCS treated patients 
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receive adjuvant RT 48 and the recommendation for it differs between radiotherapists as well 
as institutions 49. Overall in our series, 41% of BCS treated patients were offered post-
operative RT. It was a common practice in our centre before 2008 that no further treatment 
was suggested for patients with clear pathological margins 10 mm or more. After previous 
analysis of patient outcome, selective RT was introduced 50. RT was then recommended 
after BCS to those with high grade DCIS, women younger than 50 years old and lesions 
more than 30mm, regardless of tumour grade, following a multidisciplinary team discussion 
3. Patients who undergo mastectomy will not receive postoperative RT regardless of the age, 
nuclear grade or lesion size.  
Conclusion: This study addresses the long-term experience of a single institution with 
DCIS management over a 30-year period. Over this time rates of successful BCS have 
improved but avoiding the need for second therapeutic operations remains a challenge. The 
dominant risk factors for failed BCS and for disease in re-excision or completion mastectomy 
specimens are young age (<40 years), symptomatic presentation, presence of comedo 
necrosis, and larger tumour size (>40mm). 
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Figure 1   
   
Figure 1: The annual rates, over the period between 1987-2017, of: A) Breast conserving surgery (BCS); shows 
the higher rates of BCS as a primary surgical choice over the years, B) Shows the comparable rates of final BCS 
after re-excisions. Obviously over the last 10 years the rates of BCS exceed the rates of mastectomy. C) Post-
operative adjuvant radiotherapy; a significant increase of radiotherapy use post-operatively after 2000 is observed. 
D) Re-excision and E) Recurrence after primary BCS; A significant decrease in both is observed over the last 10 
years.  
!
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Table 1: Clinicopathological parameters of the whole primary DCIS cohort stratified by time 
period 
 17
Parameter Total N (%)
DCIS Diagnosed 
1987-2008 
(n=803) 
N (%)
DCIS diagnosed 
2009-2017 
(n=446) 
N (%)
X2 
P-value
Age * 
   <40 
   40 to 60 
   >60
32 (3) 
688 (55) 
529 (42)
24 (3) 
467 (58) 
312 (39)
8  (2) 
221 (49) 
217 (49)
11.9 
0.003
Presentation  
   Symptomatic 
   Screening
501 (40) 
748 (60)
351 (44) 
452 (56)
150 (34) 
296 (66)
11.8 
0.001
DCIS Site ** 
   Localised  
   Diffuse
929 (85) 
160 (15)
590 (88) 
79 (12)
339 (81) 
81 (19)
11.5 
0.001
Tumour Size * 
   <16mm  
   16 to 40mm 
   >40mm
457 (37) 
484 (39) 
301 (24)
308 (39) 
304 (38) 
184 (23)
149 (33) 
180 (41) 
117 (26)
3.6 
0.160
Tumour Grade  
   Low 
   Intermediate 
   High
156 (12) 
333 (27) 
760 (61)
109 (14) 
185 (23) 
509 (64)
47 (11) 
148 (33) 
251 (56)
16.8 
<0.0001
Comedo necrosis  
   No 
   Yes
409 (33) 
840 (67)
280 (35) 
523 (65)
129 (29) 
317 (71)
4.6 
0.032
Solid DCIS 
   No  
   Pure 
   Mixed with other types
529 (42) 
291 (23) 
429 (35)
406 (50) 
164 (20) 
233 (30)
123 (28) 
127 (28) 
196 (44)
62.3 
<0.0001
Cribriform DCIS 
   No  
   Pure 
   Mixed with other types
649 (52) 
114 (9) 
486 (39)
444 (55) 
75 (10) 
284 (35)
205 (46) 
39 (9) 
202 (45)
12.1 
0.002
Papillary DCIS 
   No  
   Pure 
   Mixed with other types
1127 (90) 
42 (3) 
80 (7)
729 (91) 
26 (3) 
48 (6)
398 (89) 
16 (4) 
32 (7)
0.8 
0.663
Micropapillary DCIS 
   No  
   Pure 
   Mixed with other types
916 (73) 
79 (7) 
254 (20)
594 (74) 
53 (7) 
156 (19)
322 (72) 
26 (6) 
98 (22)
1.3 
0.520
Associated Paget’s Disease 
   No  
   Yes
559 (91) 
56 (9)
399 (90) 
43 (10)
160 (93) 
13 (7)
0.7 
0.361
Management (First Operation) 
   Mastectomy 
   Breast conserving surgery (BCS)
424 (34) 
824 (66)
292 (36) 
510 (64)
132 (30) 
314 (70)
5.9 
0.015
Margin width *** 
   Positive (Tumour on ink) 
   <2mm 
   ≥2mm 
  Unknown  
317 (39) 
88 (11) 
382 (46) 
37 (4)
240 (47) 
36 (7) 
202 (40) 
32 (6)
77 (24) 
52 (17) 
180 (57) 
5 (2)
72.5 
<0.0001
Re excision *** 
   Yes 
   No
414 (50) 
410 (50)
298 (58) 
212 (42)
116 (37) 
198 (63)
35.9 
<0.0001
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DCIS: Ductal carcinoma in situ; N: Number; X2: Chi square, P values in bold are significant  
    *Age and size were categorised according to Van Nuys Prognostic Index (VNPI) 
    ** Site; Localised: DCIS is involving one quadrant, diffuse: DCIS is in more than one quadrant  
    *** Refers to patients treated primarily with BCS (first operation)  
    **** Refers to patients treated by BCS (final operation)  
Type of re-excision *** 
   Re excision  
   Mastectomy 
232 (56) 
182 (44)
159 (53) 
139 (47)
73 (63) 
43 (37)
3.1 
0.078
Residual Tumour *** 
   No 
   Yes
196 (47) 
218 (53)
150 (50) 
148 (50)
46 (40) 
70 (60)
3.8 
0.051
Management (Final Operation)  
   Mastectomy  
   BCS
606 (49) 
642 (51)
431 (54) 
371 (46)
175 (39) 
271 (61)
24.1 
<0.0001
Radiotherapy **** 
   Yes 
   No
263 (41) 
379 (59)
92 (25) 
279 (75)
171 (63) 
100 (37)
127.1 
<0.0001
VNPI (after 1st operation)*** 
   Low risk 
   Moderate risk 
   High risk 
195 (25) 
470 (60) 
118 (15)
105 (22) 
288 (61) 
81 (17)
90 (29) 
182 (59) 
37 (12)
7.1 
0.030
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 Table 2: Clinicopathological factors associated with the selection of type of primary surgery 
for DCIS management stratified by time period 
Parameter DCIS Diagnosed 
1987-2008 
N (%)
X2 
p-
value
DCIS diagnosed 
2009-2017 
N (%)
X2 
p-
value
Total 
N (%) X2 
p-
value
BCS
Mastect
omy
BCS
Mastect
omy 
BCS
Mastecto
my 
Age  
   <40 
   40 to 60 
   >60
13 (54) 
297 
(64) 
200 
(64)
11 (46) 
170 (36) 
111 (36)
0.9 
0.610
5 (63) 
150 
(68) 
159 
(73)
3 (37) 
71 (32) 
58 (27)
1.8 
0.412
18 (56) 
447 
(65) 
359 
(68)
14 (44) 
241 (35) 
169 (32)
2.6 
0.271
Presentation  
   Symptomatic 
   Screening
204 
(58) 
306 
(68)
146 (42) 
146 (32)
7.6 
0.006
84 (56) 
230 
(78)
66 (44) 
66 (22)
22.5 
<0.00
01
288 
(58) 
536 
(72)
212 (42) 
212 (28)
26.4 
<0.00
01
Site  
   Localised 
   Diffuse 
365 
(62) 
30 (38)
224 (38) 
49 (62)
51.7 
<0.00
01
250 
(74) 
45 (56)
89 (26) 
36 (44)
10.5 
0.005
615 
(66) 
75 (47)
313 (34) 
85 (53)
48.6 
<0.00
01
Size 
   <16mm  
   16 to 40mm 
   >40mm
256 
(83) 
175 
(58) 
75   
(41)
52 (17) 
129 (42) 
109 (59)
96.9 
<0.00
01
133 
(89) 
134 
(74) 
47   
(40)
16 (11) 
46 (26) 
70 (60)
78.1 
<0.00
01
389 
(85) 
309 
(64) 
122 
(41)
68 (15) 
175 (36) 
179 (59)
162.5 
<0.00
01
Grade  
   Low 
   Intermediate 
   High
92 (84) 
133 
(72) 
285 
(56)
17 (16) 
51 (28) 
224 (44)
39.1 
<0.00
01
41 (87) 
116 
(78) 
157 
(63)
6 (13) 
32 (22) 
94 (37)
18.3 
<0.00
01
133 
(85) 
249 
(75) 
442 
(58)
23 (15) 
83 (25) 
318 (42)
58.6 
<0.00
01
Comedo necrosis  
   No 
   Yes
215 
(77) 
295 
(56)
64 (23) 
228 (44)
33.5 
<0.00
01
109 
(85) 
205 
(65)
20 (15) 
112 (35)
17.3 
<0.00
01
324 
(79) 
500 
(60)
84 (21) 
340 (40)
48.4 
<0.00
01
Solid DCIS 
   No 
   Pure 
   Mixed with other 
types
273 
(67) 
103 
(63) 
134 
(58)
132 (33) 
61 (37) 
99 (42)
6.3 
0.043
95 (77) 
89 (70) 
130 
(66)
28 (23) 
38 (30) 
66 (34)
4.3 
0.115
368 
(70) 
192 
(66) 
264 
(62)
160 (30) 
99 (34) 
165 (38)
7.1 
0.030
Cribriform DCIS 
   No 
   Pure 
   Mixed with other 
types
274 
(62) 
59 (79) 
177 
(62)
169 (38) 
16 (21) 
107 (38)
8.1 
0.017
143 
(70) 
33 (85) 
138 
(68)
62 (30) 
6 (15) 
64 (32)
4.2 
0.120
417 
(64) 
92 (81) 
315 
(65)
231 (36) 
22 (19) 
171 (35)
12.1 
0.002
Papillary DCIS 
   No 
   Pure 
   Mixed with other 
types
458 
(63) 
21 (84) 
31 (65)
271 (37) 
4 (16) 
17 (35)
4.7 
0.095
270 
(68) 
15 (94) 
29 (91)
128 (32) 
1 (6) 
3 (9)
11.7 
0.003
728 
(65) 
36 (88) 
60 (75)
399 (35) 
5 (12) 
20 (25)
12.6 
0.002
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DCIS: Ductal carcinoma in situ; N: Number; X2: Chi square, BCS: Breast conserving surgery, p values in bold are 
significant  
Micropapillary 
DCIS 
   No 
   Pure 
   Mixed with other 
types
391 
(66) 
33 (62) 
86 (55)
202 (34) 
20 (38) 
70 (45)
6.3 
0.043
236 
(73) 
14 (54) 
64 (65)
86 (27) 
12 (46) 
34 (35)
5.9 
0.052
627 
(69) 
47 (60) 
150 
(59)
288 (31) 
32 (40) 
104 (41)
9.6 
0.008
Associated 
Paget’s  
   No  
   Yes
143 
(36) 
7 (16)
256 (64) 
36 (84)
6.6 
0.010
40 (25) 
3 (23)
120 (75) 
10 (77)
0.1 
0.877
183 
(33) 
10 (18)
376 (67) 
46 (82)
5.2 
0.022
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Table 3: Detailed surgical management of the DCIS cases as a whole cohort   
BCS: Breast conserving surgery; n: number 
Surgical management
Primary 
operation 
Mastectomy 
(n=424) 
(34%) 
BCS 
(n=824) 
66% 
Re excisions
Yes (n=414)  
(50%)
No re-excision (n=410) 
(50%)Mastectomy Re-excision
n=182 (44%) n= 232 (56%)
Final 
operation 
Mastectomy 
(n=606) 
(49%)
BCS 
(n=642) 
(51%)    
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Table 4: Clinicopathological factors associated with re excision after primary treatment with 
breast conserving surgery stratified by time period 
Parameter
DCIS Diagnosed 
1987-2008 
N (%)
X2 
p-
value
DCIS diagnosed 
2009-2017 
N (%)
X2 
p-
value
Total
X2 
p-
value
No Yes No Yes No Yes
Age  
   <40 
   40 to 60 
   >60
3 (23) 
113 
(38) 
96 (48)
10 (77) 
184 (62) 
104 (52)
6.7 
0.034
3 (60) 
95 (63) 
100 
(63)
2 (40) 
55 (37) 
59 (37)
0.1  
0.987
6 (33) 
208 
(46) 
196 
(55)
12 (67) 
239 
(54) 
163 
(45)
7.2   
0.028
Presentation  
   Symptomatic 
   Screening
65 (32) 
147 
(48)
139 (68) 
159 (52)
13.2 
<0.00
01
41 (49) 
157 
(68)
43 (51) 
73 (32)
9.9 
0.002
106 
(37) 
304 
(57)
182 
(63) 
232 
(43)
29.7 
<0.00
01
Site  
   Localised   
   Diffuse 
157 
(43) 
13 (43)
208 (57) 
17 (57)
1.6 
0.459
169 
(68) 
21 (47)
81 (32) 
24 (53)
10.9 
0.004
326 
(53) 
34 
(45)
289 
(47) 
41 (55)
11.5 
0.003
Size 
  <16mm  
   16 to 40mm 
   >40mm
133 
(52) 
66 (38) 
10 (13)
123 (48) 
109 (62) 
65 (87)
37.1 
<0.00
01
112 
(84) 
69 (51) 
17 (36)
21 (16) 
65 (49) 
30 (64)
47.8 
<0.00
01
245 
(63) 
135 
(44) 
27 
(22)
144 
(37) 
174 
(56) 
95 (78)
69.1 
<0.00
01
Grade  
   Low 
   Intermediate 
   High
34 (37) 
57 (44) 
121 
(42)
58 (63) 
76 (56) 
164 (58)
0.9 
0.610
27 (66) 
68 (59) 
103 
(66)
14 (34) 
48 (41) 
54 (34)
1.6 
0.459
61 
(46) 
125 
(50) 
224 
(51)
72 (54) 
124 
(50) 
218 
(49)
0.9 
0.614
Comedo necrosis  
   No 
   Yes
81 (38) 
131 
(44)
134 (62) 
164 (56)
2.3 
0.128
62 (57) 
136 
(66)
47 (43) 
69 (34)
2.7 
0.098
143 
(44) 
267 
(53)
181 
(56) 
233 
(47)
6.7 
0.009
Solid DCIS 
   No 
   Pure 
   Mixed with other 
types
98 (36) 
55 (53) 
59 (44)
175 (64) 
48 (47) 
75 (56)
9.8 
0.007
59 (62) 
67 (75) 
72 (55)
36 (38) 
22 (25) 
58 (45)
9.1 
0.011
157 
(43) 
122 
(64) 
131 
(50)
211 
(57) 
70 (36) 
133 
(50)
22.1 
<0.00
01
Cribriform DCIS 
   No 
   Pure 
   Mixed with other 
types
108 
(39) 
27 (46) 
77 (44)
166 (61) 
32 (54) 
100 (56)
1.2 
0.543
97 (68) 
23 (70) 
78 (56)
46 (32) 
10 (30) 
60 (44)
4.5 
0.103
205 
(49) 
50 
(54) 
155 
(49)
212 
(51) 
42 (46) 
160 
(51)
0.9 
0.646
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    DCIS: Ductal carcinoma in situ; VNPI: Van Nuys Prognostic Index; N: Number; X2: Chi square, p values in bold 
are significant  
Papillary DCIS 
   No 
   Pure 
   Mixed with other 
types
188 
(41) 
10 (48) 
14 (45)
270 (59) 
11 (52) 
17 (55)
0.5 
0.766
168 
(62) 
13 (87) 
17 (59)
102 (38) 
2 (13) 
12 (41)
3.9 
0.141
356 
(49) 
23 
(64) 
31 
(52)
372 
(51) 
13 (36) 
29 (48)
3.2 
0.204
Micropapillary 
DCIS 
   No 
   Pure 
   Mixed with other 
types
175 
(45) 
6 (18) 
31 (36)
216 (55) 
27 (82) 
55 (64)
10.1 
0.006
160 
(68) 
  7  (50) 
31 (48)
76 (32) 
7 (50) 
33 (52)
9.2 
0.010
335 
(53) 
13 
(28) 
62 
(41)
292 
(47) 
34 (72) 
88 (59)
16.8 
<0.00
01
Margin width  
   Positive (tumour 
on ink) 
   <2mm 
   ≥2mm
8 (3) 
9 (25) 
165 
(82)
232 (97) 
27 (75) 
37 (18)
318.7 
<0.00
01
3 (4) 
18 (35) 
175 
(97)
74 (96) 
34 (65) 
5 (3)
225.1 
<0.00
01
11 (3) 
27 
(31) 
340 
(89)
306 
(97) 
61 (69) 
42 (11)
543.7 
<0.00
01
VNPI (1st 
operation)  
   Low risk 
   Moderate risk 
   High risk
73 (70) 
103 
(36) 
5 (6)
32 (30) 
185 (64) 
76 (94)
108.9 
<0.00
01
82 (91) 
109 
(60) 
5 (13)
8 (9) 
73 (40) 
32 (87)
71.3 
<0.00
01
155 
(79) 
212 
(45) 
10 (8)
40 (21) 
258 
(55) 
108 
(92)
168.9 
<0.00
01
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Table 5: Multivariate logistic regression model analysis showing the association between 
the various clinicopathological parameters and; a) selection of type of primary surgery for 
DCIS management (BCS versus mastectomy), b) re-excision after primary treatment with 
BCS, c) type of the re-excision surgery either another conservative operation or completion 
mastectomy and, d) presence of residual tumour tissue in the re excision specimens 
A) 
p values in bold are significant 
*DCIS extent refers to either localised DCIS involving one quadrant or diffuse that 
involves more than one breast quadrant.  
Parameter
DCIS Diagnosed 
1987-2008
DCIS Diagnosed 
2009-2017
Whole Cohort 
Hazard 
Ratio
95%CI p-
value
Hazard 
Ratio
95%CI p-value Hazard 
Ratio
95%CI p-value
Patient age 2.1 0.6-6.8 0.26
1
2.2 0.2-22.5 0.512 2.3 0.8-6.3 0.121
DCIS 
presentation 
0.7 0.4-1.1 0.13
4
1.1 0.5-2.6 0.823 0.8 0.5-1.2 0.275
DCIS site 
(extent)
2.2 1.1-4.4 0.03
0
0.9 0.3-2.2 0.773 1.7 0.9-2.8 0.058
DCIS size 1.2 0.6-2.2 0.63
2
1.8 0.7-4.5 0.219 1.2 0.7-1.8 0.527
DCIS Nuclear 
grade
1.8 1.1-3.2 0.04
2
0.9 0.1-6.1 0.923 1.5 0.9-2.5 0.082
Comedo 
necrosis 
1.7 0.9-2.9 0.07
5
6.4 1.8-23.1 0.004 2.3 1.4-3.8 0.001
DCIS 
Histological 
type
1.5 0.9-2.4 0.07
6
0.6 0.2-1.5 0.279 1.2 0.8-1.8 0.381
Presence of 
Paget’s Disease 
2.5 1.1-6.2 0.04
5
0.5 0.1-2.4 0.402 1.8 0.8-3.9 0.130
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B) 
p values in bold are significant 
C) 
p values in bold are significant 
Parameter
DCIS Diagnosed 
1987-2008
DCIS Diagnosed 
2009-2017
Whole Cohort 
Hazard 
Ratio
95%CI p-
value
Hazard 
Ratio
95%CI p-value Hazard 
Ratio
95%CI p-value
Patient age 2.2 0.1-68.3 0.66
1
0.5 0.2-1.3 0.155 0.9 0.1-8.6 0.974
DCIS 
presentation 
1.2 0.5-2.9 0.64
6
0.2 0.1-0.9 0.041 1.2 0.6-2.2 0.635
DCIS site 
(extent)
0.1 0.01-0.2 0.00
1
1.4 0.2-6.7 0.711 0.2 0.1-0.5 0.002
DCIS size 1.5 0.3-8.1 0.64
4
2.1 0.3-13.7 0.439 2.8 1.1-6.9 0.026
DCIS Nuclear 
grade
0.4 0.1-1.2 0.11
4
1.7 0.2-14.7 0.649 0.6 0.2-1.5 0.280
Comedo 
necrosis 
0.6 0.2-1.6 0.33
6
0.3 0.1-1.3 0.103 0.4 0.2-0.9 0.046
DCIS 
Histological 
type
1.2 0.5-2.8 0.60
5
1.6 0.5-4.9 0.409 1.4 0.8-2.4 0.282
Margin status  0.1 0.07-0.2 <0.0
001
0.1 0.03-0.2 <0.00
01
0.1 0.02-0.2 <0.000
1
Parameter
DCIS Diagnosed 
1987-2008
DCIS Diagnosed 
2009-2017
Whole Cohort 
Hazard 
Ratio
95%CI p-
value
Hazard 
Ratio
95%CI p-value Hazard 
Ratio
95%CI p-value
Patient age 1.5 0.8-2.9 0.23
3
1.6 0.6-4.4 0.351 1.5 0.9-2.5 0.143
DCIS 
presentation 
2.3 1.2-4.5 0.01
4
1.9 0.6-6.1 0.230 2.4 1.4-4.1 0.001
DCIS site 
(extent)
0.5 0.1-1.8 0.28
9
0.8 0.3-2.7 0.758 0.6 0.2-1.3 0.158
DCIS size 10.4 3.9-27.8 <0.0
001
5.2 1.5-18.5 0.010 9.7 4.4-21.5 0.0001
DCIS Nuclear 
grade
1.1 0.4-3.0 0.92
9
3.1 0.8-11.9 0.084 1.3 0.5-3.2 0.590
Comedo 
necrosis 
1.6 0.7-3.5 0.26
2
0.2 0.1-0.8 0.028 0.9 0.5-1.8 0.896
DCIS 
Histological 
type
1.3 0.7-2.4 0.49
1
0.8 0.3-2.6 0.748 0.9 0.5-1.6 0.856
Margin status  0.2 0.1-0.6 0.00
2
1.1 3.6-7.3 <0.00
01
0.3 0.1-0.7 0.005
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D) 
p values in bold are significant 
*Type of re-excision either another conservative surgery or completion mastectomy.
Parameter
DCIS Diagnosed 
1987-2008
DCIS Diagnosed 
2009-2017
Whole Cohort 
Hazard 
Ratio
95%CI p-
value
Hazard 
Ratio
95%CI p-value Hazard 
Ratio
95%CI p-value
Patient age 0.7 0.1-5.4 0.73
1
0.9 0.3-2.2 0.771 1.2 0.7-2.1 0.490
DCIS 
presentation 
1.8 0.9-3.6 0.08
2
4.4 1.3-14.6 0.017 2.1 1.2-3.7 0.007
DCIS site 
(extent)
1.1 0.3-4.3 0.84
5
0.2 0.1-0.8 0.023 0.6 0.3-1.4 0.262
DCIS size 4.1 1.6-10.9 0.00
4
4.7 1.1-19.7 0.034 4.2 1.9-9.4 0.0002
DCIS Nuclear 
grade
0.7 0.2-2.2 0.59
6
1.2 0.3-4.1 0.794 0.7 0.4-1.4 0.297
Comedo 
necrosis 
2.3 0.9-5.2 0.05
1
0.9 0.3-3.9 0.950 2.0 1.1-3.9 0.042
DCIS 
Histological 
type
1.3 0.7-2.6 0.35
9
2.1 0.7-5.6 0.162 1.8 1.1-2.9 0.030
Margin status 2.2 0.6-9.1 0.25
7
0.3 0.1-4.5 0.442 1.3 0.5-3.4 0.626
Type of re-
excision*
4.8 2.4-9.5 0.00
01
2.5 0.8-7.9 0.119 3.3 1.9-5.7 0.0001
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